2009
Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS)
Rao V, Price S, Perkins K, Aldridge P, Tretler J, Davis J, Dale J, Gill F, Hartman K, Stork L, Gnarra D, Krishnamurti L, Newburger P, Puck J, Fleisher T. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatric Blood & Cancer 2009, 52: 847-852. PMID: 19214977, PMCID: PMC2774763, DOI: 10.1002/pbc.21965.Peer-Reviewed Original ResearchConceptsAutoimmune lymphoproliferative syndromeAutoimmune hemolytic anemiaRefractory immune thrombocytopeniaMedian response durationUse of rituximabDisorder of apoptosisMarked lymphadenopathyProlonged neutropeniaRituximab infusionRituximab useSurgical splenectomyALPS patientsImmune thrombocytopeniaPalpable spleenRituximab therapySignificant splenomegalyPolysaccharide vaccineAutoimmune destructionMedication optionsMultilineage cytopeniasRefractory cytopeniaAutoreactive lymphocytesAsplenic individualsAntibody responseLymphoproliferative syndrome
2008
Stable Long-Term Donor Engraftment following Reduced-Intensity Hematopoietic Cell Transplantation for Sickle Cell Disease
Krishnamurti L, Kharbanda S, Biernacki M, Zhang W, Baker K, Wagner J, Wu C. Stable Long-Term Donor Engraftment following Reduced-Intensity Hematopoietic Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2008, 14: 1270-1278. PMID: 18940682, DOI: 10.1016/j.bbmt.2008.08.016.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnemia, Sickle CellChildCyclosporineFemaleGraft SurvivalGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansImmunosuppressive AgentsLiving DonorsMaleMycophenolic AcidMyeloablative AgonistsSiblingsTransplantation ChimeraTransplantation ConditioningTransplantation, HomologousConceptsHematopoietic stem cell transplantationSickle cell diseaseRIC regimenCell transplantationCell diseaseEfficacy of HSCTHigh-risk sickle cell diseaseReduced-Intensity Hematopoietic Cell TransplantationAllogeneic hematopoietic stem cell transplantationReduced-intensity conditioning regimensEquine antithymocyte globulinHost disease (GVHD) prophylaxisTotal lymphoid irradiationAcceptable therapeutic optionHematopoietic cell transplantationGroup of patientsStem cell transplantationAntithymocyte globulinLymphoid irradiationConditioning regimenMycophenolate mofetilConditioning regimensDisease prophylaxisDonor engraftmentTherapeutic options